Trial reportRadiation oncology (London, England)2025
Hypofractionated radiotherapy with hyperthermia in radiation-associated and in-volume recurrent soft tissue sarcomas of the extremities and trunk wall: results of a proof-of-concept prospective trial.
Trial report in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04398095 (Hyperthermia and Radiotherapy in the Treatment for In-field Recurrent and Radiation-induced Soft Tissue and Bone Sarcomas), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hyperthermia and Radiotherapy in the Treatment for In-field Recurrent and Radiation-induced Soft Tissue and Bone Sarcomas
Who cites it
1 citing paper in PubMed.
- Advances in Radiotherapy for Soft Tissue Sarcomas in 2025: A Review.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRadiation-associated sarcomas (RAS) and in-volume recurrent sarcomas (IRS) are significant therapeutic challenges due to prior radiotherapy (RT) exposure and the risks associated with re-irradiation. The aim of this study was to evaluate the safety and efficacy of moderately hypofractionated RT combined with locoregional hyperthermia (HT) in patients with RAS/IRS.
methodsA prospective, proof-of-concept, single-arm, phase II clinical trial (NCT04398095) was conducted in which 20 patients with locally advanced RAS/IRS of the extremities and trunk wall were enrolled. Treatment consisted of RT at 36 Gy in 12 fractions over three weeks, combined with at least weekly HT sessions. Unresectable tumors received an integrated boost to 42 Gy. The primary endpoint was grade 3 or higher late toxicity according to the Common Terminology Criteria for Adverse Events version 5.0 at 18 months, while secondary endpoints included local control, progression-free survival (PFS), and cancer-specific survival (CSS).
resultsMedian follow-up was 48.9 months. No patient developed grade ≥ 3 late toxicity. Seven patients (35%) experienced local progression. No local progression was observed in the unresectable group treated with integrated boost. All tumors showed radiologic response (partial or stable disease). We observed up to 10% viable tumor cells in the postoperative specimens of five of the 12 patients who underwent surgery. One- and two-year PFS were 70% and 45%, respectively; CSS was 95% and 90%, respectively.
conclusionsModerately hypofractionated RT with HT is a safe approach for RAS/IRS reirradiation. Dose escalation may improve local control and warrants further investigation in larger studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.